• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Functional elucidation and therapeutic application of protease in kidney injury by metabolic syndrome

Research Project

Project/Area Number 15K19460
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Kidney internal medicine
Research InstitutionKumamoto University

Principal Investigator

Mizumoto Teruhiko  熊本大学, 医学部附属病院, 特任助教 (80749193)

Project Period (FY) 2015-04-01 – 2017-03-31
Project Status Completed (Fiscal Year 2016)
Budget Amount *help
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords尿蛋白 / メタボリックシンドローム / セリンプロテアーゼ / 糸球体障害 / プロテアーゼ / カモスタット / アポトーシス / 上皮細胞 / 糸球体傷害
Outline of Final Research Achievements

Severe proteinuria observed in the High salt group were substantially attenuated by both Camostat and Hydralazine. The reduction levels in BP were comparable, but the anti-proteinuric effect of camostat was much greater than that of Hydralazine. High salt diet induced apoptosis of glomerular epitherial cells through activation of mineralocorticoid receptor. This study suggested that serine protease inhibitor attenuates apoptosis of glomerular epithelial cells and improves urinary protein. Taken together, camostat showed an anti-proteinuric effect by defending podocyte from apoptosis beyond its anti-hypertensive action.

Report

(3 results)
  • 2016 Annual Research Report   Final Research Report ( PDF )
  • 2015 Research-status Report
  • Research Products

    (3 results)

All 2016 2015

All Journal Article (3 results) (of which Peer Reviewed: 3 results,  Open Access: 3 results,  Acknowledgement Compliant: 2 results)

  • [Journal Article] A serine protease inhibitor attenuates aldosterone-induced kidney injuries via the suppression of plasmin activity.2016

    • Author(s)
      Y. Kakizoe, Y. Miyasato, T. Onoue, T. Nakagawa, M. Hayata, K. Uchimura, J. Morinaga, T. Mizumoto, M. Adachi, T. Miyoshi, Y. Sakai, K. Tomita, M. Mukoyama, K. Kitamura
    • Journal Title

      Journal of Pharmacological Sciences

      Volume: 132 Issue: 2 Pages: 145-153

    • DOI

      10.1016/j.jphs.2016.09.005

    • Related Report
      2016 Annual Research Report
    • Peer Reviewed / Open Access / Acknowledgement Compliant
  • [Journal Article] Combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model.2016

    • Author(s)
      Yuki Narita, Miki Ueda, Kohei Uchimura, Yutaka Kakizoe, Yoshikazu Miyasato, Teruhiko Mizumoto, Jun Morinaga, Manabu Hayata, Terumasa Nakagawa, Masataka Adachi, Taku Miyoshi, Yoshiki Sakai, Daisuke Kadowaki, Sumio Hirata, Masashi Mukoyama, Kenichiro Kitamura
    • Journal Title

      Journal of Pharmacological Sciences

      Volume: 130 Issue: 2 Pages: 110-116

    • DOI

      10.1016/j.jphs.2016.01.003

    • Related Report
      2015 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects.2015

    • Author(s)
      Miki Ueda, Kohei Uchimura, Yuki Narita, Yoshikazu Miyasato, Teruhiko Mizumoto, Jun Morinaga, Manabu Hayata, Yutaka Kakizoe, Masataka Adachi, Taku Miyoshi, Naoki Shiraishi, Daisuke Kadowaki, Y Sakai, Masashi Mukoyama, Kenichiro Kitamura
    • Journal Title

      Nephron

      Volume: 129 Issue: 3 Pages: 223-232

    • DOI

      10.1159/000375308

    • Related Report
      2015 Research-status Report
    • Peer Reviewed / Open Access / Acknowledgement Compliant

URL: 

Published: 2015-04-16   Modified: 2018-03-22  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi